This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Vifor Pharma 미래 성장

Future 기준 확인 1/6

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장	14.8%
매출 성장률	8.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

LSE:0RPD - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CHF Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2024	2,353	N/A	N/A	N/A	1
12/31/2023	2,189	N/A	N/A	N/A	1
12/31/2022	1,977	N/A	N/A	N/A	1
12/31/2021	1,812	147	414	527	N/A
6/30/2021	1,753	213	169	441	N/A
3/31/2021	1,757	176	119	432	N/A
12/31/2020	1,762	139	70	424	N/A
6/30/2020	1,709	93	301	500	N/A
3/31/2020	1,732	101	350	512	N/A
12/31/2019	1,754	108	399	525	N/A
9/30/2019	1,845	129	280	439	N/A
6/30/2019	1,784	100	169	353	N/A
3/31/2019	1,711	126	44	274	N/A
12/31/2018	1,639	152	-82	194	N/A
9/30/2018	1,571	157	-110	132	N/A
6/30/2018	1,504	162	-139	70	N/A
3/31/2018	1,441	98	-83	65	N/A
12/31/2017	1,378	34	-28	60	N/A
9/30/2017	1,345	26	-15	90	N/A
6/30/2017	1,312	18	-2	120	N/A
3/31/2017	1,283	82	4	190	N/A
12/31/2016	1,254	147	10	259	N/A
9/30/2016	1,944	218	139	418	N/A
6/30/2016	2,635	290	267	577	N/A
3/31/2016	3,265	295	312	550	N/A
12/31/2015	3,896	301	358	522	N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if 0RPD's forecast earnings growth is above the savings rate (1%).

수익 vs 시장: Insufficient data to determine if 0RPD's earnings are forecast to grow faster than the UK market

고성장 수익: Insufficient data to determine if 0RPD's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: 0RPD's revenue (8.7% per year) is forecast to grow faster than the UK market (4.2% per year).

고성장 수익: 0RPD's revenue (8.7% per year) is forecast to grow slower than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if 0RPD's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Vifor Pharma 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Recent updates

Cancellation of Remaining Publicly Held Registered Shares of Vifor Pharma

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

High number of new directors

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Investor sentiment improved over the past week

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Chief Executive Officer Stefan Schulze has left the company

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Independent Director has left the company

Independent Director has left the company

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Upcoming dividend of CHF2.00 per share

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Revenue misses expectations

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

New 90-day low: CHF113

New 90-day low: CHF118

Vifor Pharma Announces Board Changes

New 90-day high: CHF137

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Market bids up stock over the past week

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

New 90-day low: CHF120

New 90-day low: CHF122

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

New 90-day low - CHF124

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

First half earnings released

New 90-day low - CHF134

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견